NEW HAVEN >> Alexion Pharmaceuticals will lay off 210 employees in the coming weeks as part of restructuring that a spokeswoman said is necessary to support the company’s long-term plans.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life ...

An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to ...

Alexion Pharmaceuticals (NASDAQ:ALXN) stock hasn’t moved much this year. But that’s not new. Despite growing its EBITDA per share by nearly 100% since 2018, the company’s stock has increased ...

Alexion Pharmaceuticals Inc. announced Wednesday an agreement to buy Syntimmune for a total value of up to $1.2 billion. Syntimmune is a clinical-stage biotechnology company, which currently has a ...

Image source: TBIT via pixabay. Alexion Pharmaceuticals' stock is off to a rough start for the year. The company's shares have traded right in lockstep with the biotech stock in general -- as ...

Shares of Alexion Pharmaceuticals (NASDAQ: ALXN), a biotech focused on rare diseases, fell 9.9% in March, according to data fromS&P Global Market Intelligence. The drop was much worse than the 2.5 ...

In response to the company reporting expectation-topping first-quarter results and sharing upbeat pipeline news, shares of Alexion Pharmaceuticals (NASDAQ: ALXN) jumped 12% as of 3:15 p.m. EDT on ...

Alexion Pharmaceuticals (NASDAQ:ALXN) stock hasn’t moved much this year. But that’s not new. Despite growing its EBITDA per share by nearly 100% since 2018, the company’s stock has increased ...